about
Directly observed therapy for treating tuberculosisCombating Tuberculosis Infection: A Forbidding ChallengeRepurposing the chemical scaffold of the anti-arthritic drug Lobenzarit to target tryptophan biosynthesis in Mycobacterium tuberculosisMultidrug-resistant tuberculosis in admitted patients at a tertiary referral hospital of BangladeshTuberculosis and HIV: a partnership against the most vulnerable.Audiologic monitoring of multi-drug resistant tuberculosis patients on aminoglycoside treatment with long term follow-upIntra-abdominal and gastrointestinal tuberculosis.Population pharmacokinetics of rifapentine and desacetyl rifapentine in healthy volunteers: nonlinearities in clearance and bioavailabilitySpinal tuberculosis: a review.Doxycycline and HIV infection suppress tuberculosis-induced matrix metalloproteinases.Drug-susceptibility patterns of Mycobacterium tuberculosis in Mpumalanga province, South Africa: possible guiding design of retreatment regimen.Structure-activity relationships at the 5-position of thiolactomycin: an intact (5R)-isoprene unit is required for activity against the condensing enzymes from Mycobacterium tuberculosis and Escherichia coli.Unusual isolated tubercolous epididymitis. Case report.Which agents should we use for the treatment of multidrug-resistant Mycobacterium tuberculosis?The efficacy of the crude root bark extracts of Erythrina abyssinica on rifampicin resistant Mycobacterium tuberculosis.Microbial synthetic biology for human therapeutics.The indirect cost due to pulmonary Tuberculosis in patients receiving treatment in Bauchi State-Nigeria.Treatment for LTBI in contacts of MDR-TB patients, Federated States of Micronesia, 2009-2012.Solid-phase total synthesis of kahalalide A and related analogues.A randomized, controlled dose-finding Phase II study of the M72/AS01 candidate tuberculosis vaccine in healthy PPD-positive adults.Prevention of hepatotoxicity due to anti tuberculosis treatment: a novel integrative approach.New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development.Phomapyrrolidones A-C, antitubercular alkaloids from the endophytic fungus Phoma sp. NRRL 46751.Lipiarmycin targets RNA polymerase and has good activity against multidrug-resistant strains of Mycobacterium tuberculosis.Diarylquinolines, synthesis pathways and quantitative structure--activity relationship studies leading to the discovery of TMC207.Treatment default and death among tuberculosis patients in Hunan, China.Effects of four Indian medicinal herbs on Isoniazid-, Rifampicin- and Pyrazinamide-induced hepatic injury and immunosuppression in guinea pigs.Novel magnetic resonance imaging scoring system for diagnosis of spinal tuberculosis: A preliminary report.Genetic and phenotypic characterization of drug-resistant Mycobacterium tuberculosis isolates in Hong Kong.Pneumonia: ... and to tuberculosis as differential diagnosis in community acquired pneumonia.Modeling the interactions of herbal drugs to beta-ketoacyl ACP synthase of Mycobacterium tuberculosis H37Rv.Systematic evaluation of structure-activity relationships of the riminophenazine class and discovery of a C2 pyridylamino series for the treatment of multidrug-resistant tuberculosis.Antituberculosis therapy-induced acute liver failure: magnitude, profile, prognosis, and predictors of outcome.Cost of treatment for multidrug-resistant tuberculosis in South Korea.Antimycobacterial activity of fractions and isolated compounds from Vetiveria zizanioides
P2860
Q24187767-9EC255C1-B9B5-4BDB-BE1E-162FB9B6417FQ26750683-0F8A25B4-946F-4E1C-BEE4-8D00DFB7A7D2Q27689472-9294D75A-55DD-4E6C-B37F-0F49241C4973Q28481253-74AAD46B-F65C-4428-879A-2111E136CEC1Q30336184-537B9DC9-73BA-47EB-82F4-7DE94E2F55DEQ30838132-4087FD6D-4FC9-426A-A9A1-BCE1F72B02BFQ33299010-FF1435DF-3124-401A-ADA3-48F8C0F653A2Q33798061-A0F52070-194E-428D-A3B8-F9569EDEA4C2Q34236085-069C5970-E08E-493A-9AF0-F7C16694C1E5Q34255402-7717F58E-FBFF-41EC-B5B2-527BF138B1B7Q34288585-D972575A-8226-4884-ADDC-FA3B5A787AF1Q34619663-A9A48143-BD7B-4D8A-874D-DA6BD04C5596Q35063334-6EF2D53F-4BBB-4453-94CC-35AD35B8C00FQ35849799-DE095C4A-A815-4E5C-B18C-08D8418437EDQ35996979-F6B06581-4441-47BC-831C-32A2ECB347A4Q36179139-E2DDF204-B296-41A5-A90A-FCA0232BA2C9Q36226655-7288255C-1107-436F-9CDF-603865925058Q36511908-A95903E5-F9AB-431C-89E6-ACFFA39B545EQ37029182-A2BF21EF-C6BE-46D6-8650-607E0E90C1FBQ37301506-C6C3ADD2-C527-4F10-A5CF-F29600A54CCFQ37336390-8ECA7A31-A6E1-460A-80D6-C4AA86A56C2BQ37346929-E20E4196-A0EB-4073-949B-8476A169ABF2Q37495417-9D06CAE6-3392-464C-9708-0C79B11A3CF2Q39152809-CC5479C8-7FB4-4E78-8CEC-41C441666845Q39712350-3E6AA7B7-0CA5-42C4-92C6-ECB8AE25BCA8Q39916349-394479F9-8CED-48BC-9085-D5A4081969F6Q40816875-8C04C70D-0DEA-48BB-8728-2A00CD5EE6C6Q41884972-C78D9A5A-FB9B-4E90-B5CC-D85547D25654Q42182714-305603D7-ED64-4C2C-9814-43345E50F5B2Q42530539-27351B04-1743-4501-8438-7C5DD9D767B6Q42645638-510E6EBB-B19C-46EB-BAD5-4E953F1AB668Q42718752-1B113BCC-DDBF-425D-95BF-93A49DBF568DQ43145214-23130080-85B4-42D6-8DB3-80957897C6CBQ44799659-3306D9A6-22D4-4DBD-A37B-32CC1782E5E5Q57781156-F13625B0-D10E-4D00-B57C-CF3CDA955DB8
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Current medical treatment for tuberculosis.
@ast
Current medical treatment for tuberculosis.
@en
type
label
Current medical treatment for tuberculosis.
@ast
Current medical treatment for tuberculosis.
@en
prefLabel
Current medical treatment for tuberculosis.
@ast
Current medical treatment for tuberculosis.
@en
P2860
P1433
P1476
Current medical treatment for tuberculosis.
@en
P2093
Edward D Chan
Michael D Iseman
P2860
P304
P356
10.1136/BMJ.325.7375.1282
P407
P577
2002-11-01T00:00:00Z